Humacyte, Inc. (HUMA)Healthcare | Biotechnology | Durham, United States | NasdaqGS
0.44 USD
+0.00
(0.455%)
⇧
(Oct. 16, 2026, 12:36 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 8:14 a.m. EDT
The investment case for Humacyte is currently broken by a perfect storm of deteriorating fundamentals and overwhelming market skepticism. The company is trapped in a multi-year decline, having lost over 85% of its value since the beginning of the observation window, with the most recent annual performance showing another sharp drop. Financially, the picture is dire: the company is burning cash aggressively with negative operating cash flow and free cash flow, while posting massive losses that result in negative earnings per share and a negative return on equity. Despite a recent uptick in revenue growth, the balance sheet remains fragile with high debt relative to equity, and the market has priced in a severe discount, trading at a premium to book value despite having no earnings to justify it. The short-term outlook offers no relief. Technical indicators confirm a downtrend, with the stock trading significantly below both its 50-day and 200-day moving averages, suggesting persistent selling pressure. The options market reinforces this pessimism; there is virtually no speculative capital flowing into calls, while put buyers are actively positioning for continued weakness or a failed rebound. With no dividend to provide income and a high risk of dilution or further distress financing required to sustain operations, this is a high-risk speculative vehicle with no margin of safety for the average investor. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.122178 |
| AutoARIMA | 0.122181 |
| MSTL | 0.127793 |
| AutoTheta | 0.274129 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 31% |
| H-stat | 4.01 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.232 |
| Excess Kurtosis | -1.10 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 213.941 |
| Revenue per Share | 0.011 |
| Market Cap | 122,647,872 |
| Forward P/E | -1.78 |
| Beta | 2.44 |
| Website | https://www.humacyte.com |
As of Oct. 10, 2026, 8:14 a.m. EDT: Options activity shows a distinct lack of bullish positioning. Call volume and open interest are negligible across all expirations, with zero in-the-money calls recorded. Conversely, put activity is concentrated in the December 2026 and January 2027 expirations, where significant open interest sits at strikes well above the current price (1.0 and 1.5), indicating a hedging strategy or bearish bets against a potential recovery. Implied volatility for puts is significantly elevated compared to calls, reflecting fear of further downside rather than anticipation of a rally.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.74418604 |
| Address1 | 2,525 East North Carolina Highway 54 |
| All Time High | 17.45 |
| All Time Low | 0.337 |
| Ask | 0.4466 |
| Ask Size | 2 |
| Audit Risk | 4 |
| Average Analyst Rating | 2.0 - Buy |
| Average Daily Volume10 Day | 8,899,470 |
| Average Daily Volume3 Month | 6,585,410 |
| Average Volume | 6,585,410 |
| Average Volume10Days | 8,899,470 |
| Beta | 2.439 |
| Bid | 0.2731 |
| Bid Size | 2 |
| Board Risk | 6 |
| Book Value | 0.113 |
| City | Durham |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.4415 |
| Current Ratio | 6.207 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 0.4597 |
| Day Low | 0.4262 |
| Debt To Equity | 213.941 |
| Display Name | Humacyte |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,786,536,000 |
| Earnings Call Timestamp Start | 1,786,536,000 |
| Earnings Timestamp | 1,786,537,800 |
| Earnings Timestamp End | 1,794,486,600 |
| Earnings Timestamp Start | 1,794,486,600 |
| Ebitda | -103,228,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -1.057 |
| Enterprise To Revenue | 51.424 |
| Enterprise Value | 109,069,264 |
| Eps Current Year | -0.4 |
| Eps Forward | -0.2475 |
| Eps Trailing Twelve Months | -0.51 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 0.57494 |
| Fifty Day Average Change | -0.13344002 |
| Fifty Day Average Change Percent | -0.23209381 |
| Fifty Two Week Change Percent | -74.4186 |
| Fifty Two Week High | 1.895 |
| Fifty Two Week High Change | -1.4535 |
| Fifty Two Week High Change Percent | -0.7670185 |
| Fifty Two Week Low | 0.337 |
| Fifty Two Week Low Change | 0.104499996 |
| Fifty Two Week Low Change Percent | 0.310089 |
| Fifty Two Week Range | 0.337 - 1.895 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,606,833,000,000 |
| Float Shares | 250,790,573 |
| Forward Eps | -0.2475 |
| Forward P E | -1.7838384 |
| Free Cashflow | -58,393,248 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 184 |
| Fullday Change | 0.002000004 |
| Fullday Change Percent | 0.4550635 |
| Fullday Price | 0.4415 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.0 |
| Gross Profits | -79,374,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.056649998 |
| Held Percent Institutions | 0.26868 |
| Implied Shares Outstanding | 277,798,105 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. Humacyte, Inc. was founded in 2004 and is headquartered in Durham, North Carolina. |
| Long Name | Humacyte, Inc. |
| Market | us_market |
| Market Cap | 122,647,872 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_107706507 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -96,668,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 156,469,782 |
| Number Of Analyst Opinions | 6 |
| Open | 0.45 |
| Operating Cashflow | -97,193,000 |
| Operating Margins | -66.492615 |
| Overall Risk | 9 |
| Payout Ratio | 0.0 |
| Phone | 919 313 9633 |
| Previous Close | 0.4395 |
| Price Eps Current Year | -1.10375 |
| Price Hint | 4 |
| Price To Book | 3.9070797 |
| Price To Sales Trailing12 Months | 57.825493 |
| Profit Margins | 0.0 |
| Quick Ratio | 5.367 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 2.0 |
| Region | US |
| Regular Market Change | 0.002000004 |
| Regular Market Change Percent | 0.4550635 |
| Regular Market Day High | 0.4597 |
| Regular Market Day Low | 0.4262 |
| Regular Market Day Range | 0.4262 - 0.4597 |
| Regular Market Open | 0.45 |
| Regular Market Previous Close | 0.4395 |
| Regular Market Price | 0.4415 |
| Regular Market Time | 1,792,168,564 |
| Regular Market Volume | 3,344,139 |
| Return On Assets | -0.49866 |
| Return On Equity | -5.47872 |
| Revenue Growth | 0.349 |
| Revenue Per Share | 0.011 |
| Sand P52 Week Change | 0.16207206 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 277,798,105 |
| Shares Percent Shares Out | 0.1058 |
| Shares Short | 29,399,293 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 29,813,381 |
| Short Name | Humacyte, Inc. |
| Short Percent Of Float | 0.1065 |
| Short Ratio | 6.29 |
| Source Interval | 15 |
| State | NC |
| Symbol | HUMA |
| Target High Price | 4.0 |
| Target Low Price | 0.5 |
| Target Mean Price | 1.625 |
| Target Median Price | 1.125 |
| Total Cash | 79,903,000 |
| Total Cash Per Share | 0.288 |
| Total Debt | 66,880,000 |
| Total Revenue | 2,121,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.51 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 0.843275 |
| Two Hundred Day Average Change | -0.401775 |
| Two Hundred Day Average Change Percent | -0.476446 |
| Type Disp | Equity |
| Volume | 3,344,139 |
| Website | https://www.humacyte.com |
| Zip | 27,713 |